# EDGAR Filing Document

**Accession Number:** 0001944885
**File Stem:** 0001193125-26-281262
**Filing Date:** 2026-6
**Character Count:** 12840
**Document Hash:** c1e6183e7ce8ef389f4754aff44a36cd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-281262.hdr.sgml**: 20260624

**ACCESSION NUMBER**: 0001193125-26-281262

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260624

**FILED AS OF DATE**: 20260624

**DATE AS OF CHANGE**: 20260624

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apollomics Inc.
- **CENTRAL INDEX KEY:** 0001944885
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41670
- **FILM NUMBER:** 261116797

**BUSINESS ADDRESS:**
- **STREET 1:** 989 EAST HILLSDALE BLVD.
- **STREET 2:** STE 220
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 1-650-209-4055

**MAIL ADDRESS:**
- **STREET 1:** 989 EAST HILLSDALE BLVD.
- **STREET 2:** STE 220
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;OMB APPROVAL | &nbsp;&nbsp;&nbsp;OMB APPROVAL | &nbsp;&nbsp;&nbsp;OMB APPROVAL |
| &nbsp;&nbsp;&nbsp;OMB Number: | &nbsp;&nbsp;&nbsp;OMB Number: | 3235-0116 |
| &nbsp;&nbsp;&nbsp;Expires: | December 31, 2026 | December 31, 2026 |
| &nbsp;&nbsp;&nbsp;Estimated average burden | &nbsp;&nbsp;&nbsp;Estimated average burden | &nbsp;&nbsp;&nbsp;Estimated average burden |
| &nbsp;&nbsp;&nbsp;hours per response | &nbsp;&nbsp;&nbsp;hours per response | 8.7 |

---

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of June 2026.** 

**Commission File Number 001-41670** 

## Apollomics Inc.
**Not Applicable** 

**(Translation of registrant's name into English)** 

**989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404** 

**(Address of principal executive office)** 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F ☐ Form 40-F

------

**Notice of Failure to Satisfy a Continued Listing Rule or Standard** 

On June 18, 2026, Apollomics Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum Market Value of Listed Securities ("MVLS") of $35 million required for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(2). The Notice further states that the Company also does not meet the alternative requirements under Nasdaq Listing Rules 5550(b)(1) and 5550(b)(3).

In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a compliance period of 180 calendar days, or until December 15, 2026, to regain compliance. The Notice has no immediate effect on the listing of the Company's securities, and the Company's securities continue to trade on Nasdaq under the symbol "APLM".

2 of 5

------

**Termination of a Material Definitive Agreement** 

In a separate corporate development, effective June 11, 2026, the Company formally terminated its Collaboration and License Agreement with Launxp International Co., Ltd. ("Launxp"). The termination was due to Launxp's failure to cure a material breach of its obligations under the agreement, specifically the failure to remit the remaining upfront payment balance of $3.8 million along with applicable interest. In accordance with the terms of the agreement, all licenses previously granted to Launxp have automatically and immediately terminated. Following Launxp's public expression of disagreement with the termination, the Company formally initiated the contractually mandated dispute resolution process on June 18, 2026.

**Financial Statements and Exhibits** 

The Company issued a press release on June 24, 2026, announcing the receipt of the Notice and the corporate update regarding the termination of the Launxp agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Form 6-K is incorporated by reference into the Company's registration statements under the Securities Act of 1933, as amended, including its registration statements on Form S-8 (File Nos. 333-272559 and 333-293148) and Form F-3 (File Nos. 333-278430, 333-278431, 333-279549, and 333-294154), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

3 of 5

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | [Press Release dated June 24, 2026](d137400dex991.htm) |

---

4 of 5

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **APOLLOMICS INC.** |
|  | (Registrant) |
| Date June 24, 2026 |  |
|  | (Signature)<sup>\*</sup> |
|  | Peter Lin, Chief Financial Officer |
|  | \* Print the name and title under the signature of the signing officer. |

---

SEC 1815 (07-22) Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

5 of 5

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g137400dsp5.jpg)

**Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value** 

**Requirement and Updates Rights for Vebreltinib (APL-101) in Asia** 

**FOSTER CITY,** CALIF. – June 24, 2026 – <u>Apollomics Inc</u>. (Nasdaq: <u>APLM</u>) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated June 18, 2026 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities ("MVLS") of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market.

Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum MVLS of $35 million, and Nasdaq Listing Rule 5810(c)(3)(C) specifies that a deficiency occurs if the MVLS falls below this threshold for 30 consecutive business days. Based on the Company's MVLS for the 30 consecutive business days from May 6, 2026, to June 17, 2026, the Company no longer meets this requirement. The Notice further states that the Company also does not meet the alternative requirements under Nasdaq Listing Rules 5550(b)(1) and 5550(b)(3).

According to Nasdaq Listing Rule 5810(c)(3)(C), the Company has a 180-calendar-day compliance period to regain compliance, which expires on December 15, 2026. If, during this period, the Company's MVLS closes at or above $35 million for a minimum of 10 consecutive business days (which may be subject to extension in Nasdaq's discretion), Nasdaq will provide the Company written confirmation of its compliance, and the matter will be closed.

In the event the Company does not regain compliance with the Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting.

The Notice has no immediate effect as to the listing of the Company's securities and the Company's securities continue to trade on Nasdaq. There can be no assurance that the Company will regain compliance.

**Corporate: Updates Rights for Vebreltinib (APL-101) in Asia** 

In a separate corporate development, effective June 11, 2026, Apollomics formally terminated its Collaboration and License Agreement with Launxp International Co., Ltd. due to Launxp's failure to cure a material breach of its obligations, specifically the failure to remit the remaining upfront payment balance of $3.8 million along with applicable interest. In accordance with the terms of the agreement, all licenses previously granted to Launxp have automatically and immediately terminated.

Following Launxp's public expression of disagreement with the termination, Apollomics formally initiated the contractually mandated dispute resolution process on June 18, 2026. This process commences with a 30-day internal negotiation period, which, if unresolved, will be followed by a subsequent escalation to the Executive Officers of both parties for further resolution. Apollomics is pursuing the recovery of the unpaid $3.8 million and associated interest, and intends to defend its termination of the agreement and its rights.

As a result of this termination, Apollomics has regained the previously licensed rights to its lead clinical asset, vebreltinib (APL-101), in Asia. Together with the rights already retained by the Company, Apollomics now holds all global rights to the asset outside of Mainland China and Macau. With this reversion, Apollomics reconsolidates its ownership across the U.S., Europe, and the broader Asia-Pacific region. This consolidated ownership allows the Company to exercise unencumbered strategic control over vebreltinib's clinical development and future commercialization in the U.S., Europe, and the broader Asia-Pacific region, maximizing Apollomics' flexibility to pursue future global partnerships and value-creating opportunities.

------

![LOGO](g137400dsp5.jpg)

**About <u>Apollomics Inc.</u>** 

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics' lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.

For more information, please visit <u>www.apollomicsinc.com</u>.

**Cautionary Statement Regarding Forward-Looking Statements** 

This press release includes statements that constitute "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics' strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "seek," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2025, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission ("SEC") under the heading "Risk Factors" and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.

**Investor Contacts** 

Peter Lin, Chief Financial Officer

Apollomics, Inc.

1-650-209-4055

<u>peter.lin@apollomicsinc.com</u> 

Peter Vozzo

ICR Healthcare

1-443-213-0505

<u>Peter.Vozzo@icrhealthcare.com</u>